v3.25.3

STOCKHOLDERS EQUITY (DEFICIT) (Details 1) - Common Stock Restricted Stock Awards (RSA) - $ / shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Non-vested, beginning of period	140,221
Granted	38,378	445,490
Vested	(178,599)	(295,861)
Non-vested as of end of the period		149,629
Non-vested Weighted average grant date fair value per share beginning	$ 7.96	$ 0
Weighted average grant date fair value per share, Granted	21.50	7.96
Weighted average grant date fair value per share, Vested	10.87	7.96
Non-vested Weighted average grant date fair value per share ending	$ 0	$ 7.96

Net number of non-option equity instruments granted to participants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of non-vested options outstanding.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-4

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Weighted average grant-date fair value of non-vested options outstanding.

+ References

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Weighted average grant-date fair value of options vested.

+ References

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	zivo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested
Namespace Prefix:	zivo_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_AwardTypeAxis=zivo_CommonStockRestrictedStockAwardsRSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Zivo Bioscience, Inc. 10-Q